カテゴリ： IMARC, 世界, 医療/バイオ

世界の虚血性心疾患（IHD）治療薬市場予測2023年-2028年

■ 英語タイトル：Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

調査会社IMARC社が発行したリサーチレポート（データ管理コード：IMARC23JLY129）■ 発行会社/調査会社：IMARC
■ 商品コード：IMARC23JLY129
■ 発行日：2023年7月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：147
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール
■ 販売価格オプション（消費税別）
Single UserUSD2,999 ⇒換算￥455,848見積依頼/購入/質問フォーム
Five UserUSD3,999 ⇒換算￥607,848見積依頼/購入/質問フォーム
EnterprisewideUSD4,999 ⇒換算￥759,848見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※IMARC社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の虚血性心疾患（IHD）治療薬市場予測2023年-2028年]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

IMARC社の本市場調査レポートでは、2022年に61億ドルであった世界の虚血性心疾患（IHD）治療薬市場規模が、2028年までに79億ドルに達し、予測期間中（2023-2028）に年平均4.4%成長すると予想しています。本レポートでは、虚血性心疾患（IHD）治療薬の世界市場について調査・分析し、序論、市場範囲・定義、エグゼクティブサマリー、イントロダクション、市場概況、疾患別（狭心症、心筋梗塞）分析、医薬品別（脂質異常症治療薬、カルシウムチャネル遮断薬、β遮断薬、ACE阻害薬、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、中南米）分析、SWOT分析、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目を掲載しています。また、本書には、Bayer AG、Eli Lilly and Company、Novartis International AG、Pfizer, Inc.、Sanofi S.A.、Actelion Pharmaceuticals Ltd.、Baxter International Inc.、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Companyなどの企業情報が含まれています。
・序論
・市場範囲・定義
・エグゼクティブサマリー
・イントロダクション
・市場概況
・世界の虚血性心疾患（IHD）治療薬市場規模：疾患別
- 狭心症の市場規模
- 心筋梗塞の市場規模
・世界の虚血性心疾患（IHD）治療薬市場規模：医薬品別
- 脂質異常症治療薬の市場規模
- カルシウムチャネル遮断薬の市場規模
- β遮断薬の市場規模
- ACE阻害薬の市場規模
- その他医薬品の市場規模
・世界の虚血性心疾患（IHD）治療薬市場規模：地域別
- 北米の虚血性心疾患（IHD）治療薬市場規模
- ヨーロッパの虚血性心疾患（IHD）治療薬市場規模
- アジア太平洋の虚血性心疾患（IHD）治療薬市場規模
- 中東・アフリカの虚血性心疾患（IHD）治療薬市場規模
- 中南米の虚血性心疾患（IHD）治療薬市場規模
・SWOT分析
・バリューチェーン分析
・ファイブフォース分析
・価格分析
・競争状況

Market Overview:

The global ischemic heart disease (IHD) drugs market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.9 Billion by 2028, exhibiting a growth rate (CAGR) of 4.4% during 2023-2028.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:
Angina Pectoris
Myocardial Infarction

Breakup by Drug Class:
Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents

Breakup by Region
North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:
How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
What is the breakup of the market based on the disease class?
What is the breakup of the market based on the drug class?
What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Ischemic Heart Disease (IHD) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Disease Class
6.1 Angina Pectoris
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Myocardial Infarction
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Anti-Dyslipidemic Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Calcium Channel Blockers
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Beta-Blockers
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 ACE Inhibitors
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 ARBs
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Vasodilators
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Antithrombotic Agents
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Latin America
8.5.1 Market Trends
8.5.2 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Bayer AG
13.3.2 Eli Lilly and Company
13.3.3 Novartis International AG
13.3.4 Pfizer, Inc.
13.3.5 Sanofi S.A.
13.3.6 Actelion Pharmaceuticals Ltd.
13.3.7 Baxter International Inc.
13.3.8 Boehringer Ingelheim International GmbH
13.3.9 Bristol-Myers Squibb Company
13.3.10 Amgen Inc.
13.3.11 F. Hoffmann-La Roche AG
13.3.12 GlaxoSmithKline Plc
13.3.13 Merck & Co.
13.3.14 Eisai Co., Ltd.

Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2022
Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2022
Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2022
Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2017 & 2022
Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter’s Five Forces Analysis

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のうつ病治療薬市場予測2023年-2028年
  • 世界の口内炎治療市場予測2023年-2028年
  • 世界の呼吸器診断市場予測2023年-2028年
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(IMARC23JLY129 )"世界の虚血性心疾患（IHD）治療薬市場予測2023年-2028年" (英文：Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028)はIMARC社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。